Pfizer aims to differentiate Toviaz with patient support program

Share this article:
Pfizer aims to differentiate Toviaz with patient support program
Pfizer aims to differentiate Toviaz with patient support program
Pfizer is launching Detrol follow-on Toviaz with a 12-week patient support program featuring a progress tracker, personalized emails and tips on bladder training techniques.

Patients starting on sample packs or prescriptions for the overactive bladder drug can subscribe to YourWay, a free program “developed in collaboration with experts in adherence, behavioral change and patient education and communication,” the company said.

“Patients often need additional support beyond effective medication, and physicians have limited time to provide comprehensive care,” said Sally Beatty of Pfizer communications. “This dynamic is critical because OAB is a chronic medical condition that affects about one in six Americans, yet remains under-treated.”

It's similar to support programs Pfizer offers on other brands, such as its GetQuit plan for Chantix or the MyHeartWise program for Lipitor.

Patients enrolling can choose to access the program through the website, ToviazYourWay.com, personalized weekly emails, snail mail or automated phone calls. YourWay offers tips on diet choices, bladder training techniques to help patients wait longer between bathroom breaks, information on how the drug works, and a daily progress tracker.

“Studies have shown that treatment success may be higher when behavioral therapy is used along with taking a prescription medication,” said Beatty, “yet fewer than half of OAB patients receive behavioral intervention, even from their healthcare provider.”

In addition to the program, Pfizer hopes once-daily Toviaz's flexible dosing will set it apart from predecessor Detrol LA. The new drug comes in 4 mg and 8 mg doses.

Consumer ads by McCann HumanCare will launch later in the year. Digitas is handling interactive advertising for the brand, while LyonHeart is tasked with the professional marketing assignment.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...